Mix, Michael; Reichel, Kathrin; Stoykow, Christian; Bartholomä, Mark; Drendel, Vanessa; Gourni, Eleni; Wetterauer, Ulrich; Schultze-Seemann, Wolfgang; Meyer, Philipp T.; Jilg, Cordula A. (2018). Performance of 111In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy. European journal of nuclear medicine and molecular imaging, 45(12), pp. 2062-2070. Springer-Verlag 10.1007/s00259-018-4094-0
|
Text
Mix2018_Article_PerformanceOf111In-labelledPSM.pdf - Published Version Available under License Publisher holds Copyright. Download (1MB) | Preview |
PURPOSE:
Intraoperative identification of lymph node (LN) metastases (LNM) detected on preoperative PSMA PET/CT may be facilitated by PSMA radioguided surgery with the use of a gamma probe. We evaluated the uptake of 111In-labelled PSMA ligand DKFZ-617 (referred to as 111In-PSMA-617) in unaffected LN and LNM at the level of single LN.
METHODS:
Six patients with prostate cancer (PCa) with suspicion of LNM on preoperative PSMA PET/CT underwent 111In-PSMA-617-guided lymphadenectomy (LA; four salvage LA and two primary LA). 111In-PSMA-617 (109 ± 5 MBq). was injected Intravenously 48 h prior to surgery Template LAs were performed in small subregions: common, external, obturator and internal iliac vessels, and presacral and retroperitoneal subregions (n = 4). Samples from each subregion were isolated aiming at the level of single LN. Uptake was measured ex situ using a germanium detector. Receiver operating characteristic (ROC) analysis was performed based on 111In-PSMA-617 uptake expressed as standardized uptake values normalized to lean body mass (SUL).
RESULTS:
Overall 310 LN (mean 52 ± 19.7) were removed from 74 subregions (mean 12 ± 3.7). Of the 310 LN, 35 turned out to be LNM on histopathology. Separation of the samples from all subregions resulted in 318 single specimens: 182 PCa-negative LN samples with 275 LN, 35 single LNM samples, 3 non-nodal PCa tissue samples and 98 fibrofatty tissue samples. The median SULs of nonaffected LN (0.16) and affected LN (13.2) were significantly different (p < 0.0001). Based on 38 tumour-containing and 182 tumour-free specimens, ROC analysis revealed an area under the curve of 0.976 (95% CI 0.95-1.00, p < 0.0001). Using a SUL cut-off value of 1.136, sensitivity, specificity, positive predictive value, negative predictive value and accuracy in discriminating affected from nonaffected LN were 92.1% (35/38), 98.9% (180/182), 94.6% (35/37), 98.4% (180/183) and 97.7% (215/220), respectively.
CONCLUSION:
Ex situ analysis at the level of single LN showed that 111In-PSMA-617 had excellent ability to discriminate between affected and nonaffected LN in our patients with PCa. This tracer characteristic is a prerequisite for in vivo real-time measurements during surgery.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine |
UniBE Contributor: |
Gourni, Eleni |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1619-7070 |
Publisher: |
Springer-Verlag |
Language: |
English |
Submitter: |
Sabine Lanz |
Date Deposited: |
01 Feb 2019 15:17 |
Last Modified: |
05 Dec 2022 15:25 |
Publisher DOI: |
10.1007/s00259-018-4094-0 |
PubMed ID: |
30062606 |
Uncontrolled Keywords: |
111In-PSMA; Lymph node metastases; Lymphadenectomy; Radioguided surgery |
BORIS DOI: |
10.7892/boris.125643 |
URI: |
https://boris.unibe.ch/id/eprint/125643 |